Status:
UNKNOWN
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
Lead Sponsor:
University of British Columbia
Conditions:
Prostate Cancer
Eligibility:
MALE
Phase:
PHASE3
Brief Summary
Brachytherapy, or Transperineal implantation of the prostate (TPIP), is a recognized form of treatment for localized cancer of the prostate. TPIP has been used at the British Columbia Cancer Agency (B...
Detailed Description
The suppression of testosterone to castrate levels has a definite advantage in terms of prostate volume downsizing, disease control and ease of Brachytherapy, in this patient population. The improved ...
Eligibility Criteria
Inclusion
- All patients who elect to undergo brachytherapy for the treatment of adenocarcinoma of the prostate and who are otherwise recommended treatment with LHRH agonist. All patients must have a confirmed histological diagnosis of adenocarcinoma of the prostate and elect to be treated with transperineal implantation of the prostate.
- Eligible patients will have confirmed clinical stage T1 or T2 (UICC 1997 staging system) with
- PSA \> 10 but \< 15 and Gleason score \< 7, OR
- PSA \< 10 and Gleason score = 7 OR
- Prostate volume \> 50cc as measured on trans rectal ultrasound
- While criteria 1 and 2 are mutually exclusive, criteria 3 can be present alone or in combination with criteria 1 OR 2.
- Otherwise patients should be able to give informed consent and have a life expectancy. 2 years.
Exclusion
- \-
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00175383
Start Date
June 1 2004
End Date
December 1 2013
Last Update
April 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Cancer Agency - Vancouver Island Centre
Victoria, British Columbia, Canada, V8R 6V5